210704-95-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridinemethanamine,6-amino-2-methyl-(9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Pyridinemethanamine,6-amino-2-methyl-(9CI) serves as a key building block for the creation of complex organic molecules. Its versatile chemical properties allow for a wide range of reactions, facilitating the synthesis of various organic compounds.
Used in Biochemical Research:
3-Pyridinemethanamine,6-amino-2-methyl-(9CI) has potential applications in biochemical research due to its unique properties. It can be utilized in the study of enzyme mechanisms, the development of novel bioactive molecules, and the investigation of molecular interactions within biological systems.
It is crucial to handle 3-Pyridinemethanamine,6-amino-2-methyl-(9CI) with care and ensure proper safety measures are in place when working with this chemical compound.

InChI:InChI=1/C7H11N3/c1-5-6(4-8)2-3-7(9)10-5/h2-3H,4,8H2,1H3,(H2,9,10)

Upstream product

• 183428-90-2 2-amino-5-cyano-6-methylpyridine 
• 3430-21-5 5-bromo-3-methyl-pyridin-2-ylamine 

Relevant academic research and scientific papers

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

AMINOPYRIDINE DERIVATIVES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R1 - R11 ar

Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative

Compound of formula (I): wherein: R1 represents aryl, heteroaryl or alkyl which is optionally substituted, or a group of formula —(CO)—CR6R7NR8R9 wherein R6, R7, R8 an

2,3-methano-amino acid compounds

Compound of formula (I): wherein: n represents 2 or 3, R1represents optionally substituted alkyl, cycloalkyl or optionally substituted phenyl, R2represents amino, optionally substituted amidino, optionally substituted guanidino or optionally substituted isothioureido, Ar represents aryl or heteroaryl, X1represents hydroxy or optionally substituted amino, isomers thereof, and also salts thereof with a pharmaceutically acceptable acid or base, and which medicinal products containing the same/are useful as trypsin-related serine protease inhibitors.